Table 5.
2022 World Health Organization Classification of Conjunctival Melanocytic Intraepithelial Lesions [2]
| WHO | Acceptable alternative terminology | Increased cellularity | Histologic features | Risk of association with or progression to invasive melanoma |
|---|---|---|---|---|
| Not applicable | Benign melanosis c-MIN (grades (0–1) PAM without atypia |
No/minimal | Conjunctival hypermelanosis (increased pigment in epithelial cells without melanocytic hyperplasia or atypia). Slight or focal melanocytic hyperplasia without atypia (parabasal melanocytes with condensed round nuclei, smaller than basal epithelial cell, inconspicuous nucleoli, and inconspicuous cytoplasm) may be seen | None |
| Low-grade CMIL | PAM with mild atypia c-MIN (grades 2–4) |
Yes | Predominantly basilar melanocytic proliferation with low-grade atypia (dendritic or small to moderate size polyhedral, usually non-epithelioid melanocytes with round to irregular nuclear contours, often nuclear hyperchromasia, inconspicuous nucleoli, and inconspicuous or scant cytoplasm) | Lower |
| High-grade CMIL | PAM with moderate to severe atypia c-MIN (grade 5–10) |
Yes | More confluent basilar and significant non-basilar proliferation of melanocytes with high-grade atypia (moderate to severe), evidence of intraepithelial nested and/or pagetoid growth, and epithelioid cell cytomorphology | Higher |
| Melanoma in situ | Yes | The term melanoma in situ may be used for (1) the most atypical high-grade CMILs involving close to full thickness of the epithelium, (2) histologically obvious melanomas without documented evidence of subepithelial invasion | Highest |
CMIL, conjunctival melanocytic intraepithelial lesion.